

Grape Seed and Tea Extracts and Catechin 3-Gallates Are Potent Inhibitors of α -Amylase and α -Glucosidase Activity

Meltem Yilmazer-Musa,[†] Anneke M. Griffith,[†] Alexander J. Michels,[†] Erik Schneider,[§] and Balz Frei^{*†}

[†]Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331, United States

[§]USANA Health Sciences, Inc., Salt Lake City, Utah 84120, United States

ABSTRACT: This study evaluated the inhibitory effects of plant-based extracts (grape seed, green tea, and white tea) and their constituent flavan-3-ol monomers (catechins) on α -amylase and α -glucosidase activity, two key glucosidases required for starch digestion in humans. To evaluate the relative potency of extracts and catechins, their concentrations required for 50 and 90% inhibition of enzyme activity were determined and compared to the widely used pharmacological glucosidase inhibitor, acarbose. Maximum enzyme inhibition was used to assess relative inhibitory efficacy. Results showed that grape seed extract strongly inhibited both α -amylase and α -glucosidase activity, with equal and much higher potency, respectively, than acarbose. Whereas tea extracts and catechin 3-gallates were less effective inhibitors of α -amylase, they were potent inhibitors of α -glucosidase. Nongallated catechins were ineffective. The data show that plant extracts containing catechin 3-gallates, in particular epigallocatechin gallate, are potent inhibitors of α -glucosidase activity and suggest that procyanidins in grape seed extract strongly inhibit α -amylase activity.

KEYWORDS: α -amylase, α -glucosidase, enzyme inhibition, tea, grape seed extract, catechins, diabetes

■ INTRODUCTION

Glycemic control is an effective, long-term therapy for individuals with type II diabetes mellitus, reducing the risk of both cardiovascular and neurological complications in the development of the disease.^{1,2} Glucosidase inhibitors are commonly prescribed to diabetics to reduce postprandial hyperglycemia induced by the digestion of starch in the small intestine.³ These inhibitors are designed to primarily target α -amylase and α -glucosidase, two members of exoacting glycoside hydrolase enzymes (glucosidases) found in the intestinal tract that are critical for the digestion of carbohydrates. The overall effect of inhibition is to reduce the flow of glucose from complex dietary carbohydrates into the bloodstream, diminishing the postprandial effect of starch consumption on blood glucose levels.⁴ However, the leading glucosidase inhibitors, acarbose and miglitol, are often reported to produce diarrhea and other intestinal disturbances, with corresponding intestinal pain and flatulence.^{4,5} Randomized controlled trials with glucosidase inhibitors report these gastrointestinal side effects as the most common reason for noncompliance and early subject withdrawal.⁶

The consumption of plant-based foods or supplements may be a more acceptable source of glucosidase inhibitors due to their low cost and relative safety, including a low incidence of serious gastrointestinal side effects.^{7–9} Polyphenolic fractions from plants have been shown to inhibit α -amylase and α -glucosidase activity and allow for tighter control of blood glucose.^{10–12} Rich in polyphenolic flavonoid compounds, extracts from grape seed and green tea have been of increasing interest due to their antidiabetic properties.^{13–16} Green and white teas are particularly abundant in catechins and catechin 3-gallates. The most abundant catechin 3-gallate in green and white teas, epigallocatechin gallate (EGCG), is attributed with providing many of the beneficial, antidiabetic effects of tea consump-

tion.^{13,17,18} In contrast, grape seed extract contains not only catechins and catechin 3-gallates but also oligomeric flavan-3-ols, called procyanidins.^{19,20} Procyanidins are a subclass of proanthocyanidins and make up a large percentage of total flavonoids in grape seed extract.¹⁹ Both monomeric and oligomeric flavan-3-ols interact with glucosidase enzymes^{10,21–26} and may act as effective α -glucosidase inhibitors.

Thus, we sought to determine the potential of grape seed, green tea, and white tea extracts to inhibit α -amylase and α -glucosidase activity and compare their effects to that of the pharmacological inhibitor, acarbose. In addition, catechin constituents of these extracts were also tested for their ability to act as glucosidase inhibitors.

■ MATERIALS AND METHODS

Chemicals. α -Amylase from human saliva (type IX-A; 1000 U/mg protein), α -glucosidase from *Saccharomyces cerevisiae* (type I; 10 U/mg protein), catechin (C), epicatechin (EC), epigallocatechin (EGC), EGCG, galocatechin gallate (GCG), epicatechin gallate (ECG), acarbose, and *p*-nitrophenyl α -D-glucopyranoside (pNPG) were obtained from Sigma (St. Louis, MO, USA). Tea extracts and Teavigo (DSM Nutritional Products, Heerlen, The Netherlands) were supplied by USANA Health Sciences, Inc. (Salt Lake City, UT, USA). EnzChek Ultra Amylase Assay Kit (E33651) was purchased from Life Technologies Corp. (Grand Island, NY, USA).

Extract Analysis. Catechins in the plant extracts were identified using HPLC separation and UV detection at 280 nm (Agilent, 1260 series; Santa Clara, CA, USA). Briefly, plant extracts were dissolved in

Special Issue: 5th International Conference on Polyphenols and Health

Received: March 16, 2012

Revised: June 13, 2012

Accepted: June 15, 2012

Published: June 15, 2012

purified water at a concentration of 1 mg/mL, and 1 μ L of the resulting solution was injected on a reverse-phase C18 column (Inertsil, GL Sciences, Torrance, CA, USA). Samples were initially separated with 5% 2-propanol and 0.03% formic acid for 16 min, followed by a gradient increased to 15% 2-propanol from 16 to 22 min. Catechins were quantified on the basis of reference to purified standards and expressed

Table 1. Analysis of Plant Extracts Used in This Study^a

	grape seed (%)	green tea (%)	white tea (%)	Teavigo (%)
C	6.6	0.7	0.8	nd
EC	4.9	4.5	2.5	nd
EGC	nd	11.9	8.6	nd
ECG	1.3	8.5	4.1	2.1
EGCG	nd	34.8	9.5	95.2
GCG	0.4	1.9	0.5	0.1
GC	nd	2.3	2.1	nd
CG	nd	0.5	0.2	nd
total catechins	13.2	65.1	28.3	97.4
procyanidin B1	5.3	nd	nd	nd
procyanidin B2	3.1	nd	nd	nd
procyanidin C1	1.7	nd	nd	nd
total procyanidins	81.7	ND	ND	ND
total phenolics (GAE)	86	74	34	94

^aValues are expressed as percent of total extract weight. GAE, gallic acid equivalents; nd, not detected; ND, not determined.

as a percentage of total extract weight (Table 1). Oligomeric content of grape seed extract (total procyanidins) was determined after separation on a gel organic column (Phenogel 500A; Phenomenex, Torrance, CA, USA) using tetrahydrofuran as mobile phase and absorbance at 280 nm for detection. Grape seed oligomeric proanthocyanidins (USP catalog no. 1298219) were used as a reference standard. Phenolic content was measured using a modified Folin–Ciocalteu assay, and data are expressed as gallic acid equivalents (GAE).

α -Amylase Assay. The human salivary α -amylase inhibition assay was adapted from Deutschlander et al.²⁷ and Lo Piparo et al.²⁶ Extracts were prepared by dissolution in dimethyl sulfoxide (DMSO) to a stock concentration of 10 mg/mL immediately before use in experiments. Individual catechins were also dissolved in DMSO to produce an 8 mM stock solution. Various dilutions of test compounds were preincubated in 96-well plates for 30 min at room temperature with 250 μ U of α -amylase at a final concentration of 2.5 mU/mL. The incubation buffer consisted of 50 mM NH_2PO_4 , 50 mM NaCl, 0.5 mM CaCl_2 , and 0.1% bovine serum, pH 6.0, and the final volume of the preincubation mixture was 75 μ L. To start the reaction, 25 μ L of 20 μ g/mL DQ starch substrate from the EnzChek Ultra Amylase Assay Kit (Molecular Probes, Invitrogen), prepared in incubation buffer, was added to achieve a final concentration of 5 μ g/mL starch. The final concentrations of extracts and catechins were between 0.5 and 500 μ g/mL and between 1 and 1000 μ M, respectively. DMSO concentrations ranged from 0.00625 to 6.25%. Control incubations showed no effect of these DMSO concentrations on α -amylase activity (data not shown). Acarbose was included in all experiments as a “positive” control.

Amylase enzymatic activity was monitored by digestion of the DQ starch substrate, resulting in an increase in fluorescence over time. Fluorescence was measured using a SpectraMax GeminiXS spectrofluorometer (Molecular Devices, Sunnyvale, CA, USA) with excitation and emission wavelengths of 485 and 530 nm, respectively. The linear rate of product formation during the initial 15 min of incubation was used to calculate enzyme activity. α -Amylase activity was calculated relative to control incubations without inhibitor added and expressed as a percentage of that value. Control wells with only test compound, but

no enzyme or substrate, were used to determine any background autofluorescence. Each incubation was conducted in triplicate, and the results are presented as the mean \pm standard error from at least three independent experiments, unless indicated otherwise.

α -Glucosidase Assay. The α -glucosidase inhibition assay was adapted from Deutschlander et al.²⁷ and Li et al.¹¹ Extracts and catechins were prepared as described above. The test compound and 2 mU of α -glucosidase from *S. cerevisiae* were diluted to 97 μ L in 0.1 M potassium phosphate buffer (pH 6.5) and preincubated in 96-well plates at 37 °C for 15 min. The reaction was initiated by adding 3 μ L of 3 mM pNPG as substrate. The plate was incubated for an additional 15 min at 37 °C, followed by the addition of 100 μ L of 1 M Na_2CO_3 to stop the reaction. All test compounds were prepared in DMSO as described above. The final concentrations of extracts and catechins were between 0.03 and 10 μ g/mL and between 5 and 1000 μ M, respectively. The final concentration of α -glucosidase was 20 mU/mL.

Enzyme activity was determined by measuring the release of *p*-nitrophenol from the pNPG substrate. The reaction was monitored by change of absorbance at 410 nm using a SpectraMax 190 spectrophotometer (Molecular Devices). α -Glucosidase activity was calculated relative to control wells without inhibitor added and expressed as a percentage of that value. Each incubation was conducted in triplicate, and results are presented as the mean \pm standard error from at least three independent experiments, unless indicated otherwise.

Data Analysis. Enzyme activity in the presence of inhibitors was expressed as a percentage of the uninhibited enzyme activity and was plotted against inhibitor concentration. Nonlinear regression was performed using a four-parameter logistic model and GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). As a measure of inhibitory potency, the concentrations required for 50 and 90% inhibition of enzyme activity (IC_{50} and IC_{90} , respectively) were determined. Enzyme inhibition is the reciprocal value of the enzyme activity measured, expressed as a percentage (where 0% enzyme activity equals 100% inhibition). Maximum enzyme inhibition was determined for each compound when enzyme activity was at a minimum within the concentration range of extracts or catechins tested and is reported as a measure of the compound’s inhibitory efficacy.

Statistics. Differences in calculated IC_{50} and IC_{90} values and percent maximum inhibition values were analyzed by unpaired *t* tests and one-way ANOVA employing Tukey–Kramer post hoc analysis to compare data sets (GraphPad Prism). Differences between means were considered to be significant if $p < 0.05$, as denoted in applicable tables, figures, and the text.

RESULTS

Isolated α -amylase from human saliva and α -glucosidase from *S. cerevisiae* were incubated with plant extracts (Table 1) or individual catechins, as described under Materials and Methods. Activity data in the presence of various concentrations of extracts were expressed as percent of uninhibited enzyme activity of either α -amylase (Figure 1a) or α -glucosidase (Figure 1b). As “positive” control, the pharmacological glucosidase inhibitor, acarbose, was used in parallel incubations (Figure 1c). As a measure of potency of the inhibitors tested, IC_{50} and IC_{90} values were calculated from the enzyme activity data. Likewise, as an evaluation of the efficacy of inhibition, the maximum extent of enzyme inhibition achieved by each test compound was also determined from the enzyme activity data.

α -Amylase Inhibition. The inhibitory potencies of grape seed, green tea, and white tea extracts on α -amylase activity are summarized in Table 2. As expected, acarbose showed the lowest IC_{50} , establishing its relative potency as a glucosidase inhibitor. Grape seed extract also was a strong inhibitor of α -amylase, exhibiting an IC_{50} that was slightly but nonsignificantly higher than that of acarbose. Interestingly, the IC_{90} for grape seed extract was lower than the IC_{90} for acarbose, but again this difference was not statistically significant (Table 2). Further-




Figure 1. α -Amylase and α -glucosidase inhibition by plant extracts and acarbose: dose-dependent inhibition of (a) α -amylase and (b) α -glucosidase activity by grape seed, green tea, and white tea extracts and Teavigo. (c) Inhibition of α -amylase and α -glucosidase activity by acarbose, presented on a logarithmic scale to denote differences in inhibitory potency.

more, percent enzyme inhibition at concentrations of grape seed extract at or exceeding the IC_{90} was not significantly different from the maximum inhibition achieved by acarbose (Figure 2a). These data indicate that grape seed extract is as potent and efficient as the drug, acarbose, in inhibiting α -amylase activity.

Although green tea extract has been suggested to be an effective glucosidase inhibitor,¹⁰ we observed only a moderate inhibitory effect of this extract on α -amylase activity, with calculated IC_{50} and IC_{90} values 4–7 times higher than those of acarbose and grape seed extract (Table 2). However, the

maximum extent of enzyme inhibition achieved by green tea extract was not significantly different from that of grape seed extract or acarbose (Figure 2a). These data suggest that green tea extract may act as an effective, moderately potent, inhibitor of α -amylase.

A commercially available, highly concentrated green tea extract, Teavigo ($\geq 94\%$ EGCG, Table 1), exhibited IC_{50} and IC_{90} values similar to those of green tea extract (Table 2); however, maximum enzyme inhibition was considerably lower for Teavigo compared to green tea extract (Figures 1a and 2a). In contrast, white tea extract only weakly inhibited the enzyme, with an IC_{50} >50 times higher than that of acarbose (Table 2) and about 50% enzyme inhibition at the highest concentration tested (Figures 1a and 2a).

The vast majority of flavonoids in white and green tea extracts are catechins, whereas grape seed extract also contains a significant amount of procyanidins (Table 1).^{19,20,28} To investigate whether catechins may contribute to the inhibitory effects of the various extracts tested, we determined α -amylase activity in the presence and absence of individual catechins. Consistent with the results obtained with Teavigo and tea extracts, isolated catechins were considerably less potent than acarbose or grape seed extract in inhibiting α -amylase activity (Table 2). With the exception of GCG, maximum enzyme inhibition was below 50%, even at the highest concentration tested (1 mM), such that reliable IC_{50} and IC_{90} values could not be determined (Figure 2b and Table 2).

α -Glucosidase Inhibition. Compared to its strong inhibitory effect on α -amylase, acarbose was much less potent in inhibiting α -glucosidase (Figure 1c). The IC_{50} and IC_{90} values of acarbose for α -glucosidase activity were >13 times higher than those values for α -amylase (Tables 2 and 3). Even at the highest concentration of acarbose tested (645 $\mu\text{g/mL}$, or 1 mM), about 20% of α -glucosidase activity remained (Figures 1c and 3).

Interestingly, all extracts tested were much more potent inhibitors of α -glucosidase than acarbose (Table 3). As with α -amylase, grape seed extract showed strong inhibition of α -glucosidase, but low IC_{50} and IC_{90} values were also observed for all tea extracts. Green tea extract and Teavigo exhibited significantly lower IC_{50} and IC_{90} values than grape seed and white tea extracts (Table 3). All of the extracts inhibited α -glucosidase activity by >90%, which was significantly higher than the maximum inhibition achieved by acarbose (Figures 1b and 3a).

Because Teavigo and green tea extract were the most potent inhibitors of α -glucosidase, it is likely that the constituent catechins, and specifically EGCG, would also strongly inhibit enzyme activity. As shown in Table 3, some, but not all, of the catechins tested exerted potent inhibitory effects on α -glucosidase activity. The IC_{50} values of catechins with a 3-gallate side group, that is, EGCG, GCG, and ECG, were much lower than the IC_{50} of acarbose, and, with the exception of ECG, comparable to the IC_{50} values of the extracts. Among the gallated catechins, EGCG was the most potent α -glucosidase inhibitor, with IC_{50} and IC_{90} values basically identical to those of Teavigo. Furthermore, EGCG and GCG almost completely inhibited α -glucosidase activity, whereas ECG was somewhat less effective, although the difference was not statistically significant (Figure 3b). In contrast, the nongallated catechins, C, EC, and EGC, were weak, incomplete, α -glucosidase inhibitors (Table 3 and Figure 3b).

Table 2. α -Amylase Inhibition by Tea and Grape Seed Extracts and Individual Catechins^a

extract		IC ₅₀ (μ g/mL)	IC ₉₀ (μ g/mL)	catechins		IC ₅₀ (μ g/mL)	IC ₉₀ (μ g/mL)
acarbose (control)	(n = 7)	6.9 \pm 0.8a	42.8 \pm 4.7e	C	(n = 3)	160 \pm 67bcd	>290 ^b
grape seed extract	(n = 3)	8.7 \pm 0.8ab	28.1 \pm 2.0e	EC	(n = 3)	ND	ND
green tea extract	(n = 4)	34.9 \pm 0.9c	192 \pm 15f	EGC	(n = 3)	ND	ND
Teavigo	(n = 4)	44.2 \pm 6.1c	144 \pm 19f	ECG	(n = 2)	~27	~50
white tea extract	(n = 4)	378 \pm 134d	>500 ^b	EGCG	(n = 2)	~24	~36
				GCG	(n = 2)	~17	~144

^aValues presented are the mean \pm standard error, or approximate values if incomplete inhibition was observed. Different letters denote significant differences in IC₅₀ or IC₉₀ values as determined by unpaired *t* test (*p* < 0.05). ND, not determined. ^bExceeds maximum concentration tested.




Figure 2. Efficacy of α -amylase inhibitors. Relative efficacy of α -amylase inhibition was determined as the maximum extent of inhibition (in percent, relative to uninhibited enzyme activity) achieved by either acarbose or (a) plant extracts and (b) individual catechins. Significant differences are denoted by unshared letters between columns as determined by ANOVA, as described under Materials and Methods.




Figure 3. Efficacy of α -glucosidase inhibitors. Relative efficacy of α -glucosidase inhibition was determined as the maximum extent of inhibition (in percent, relative to uninhibited enzyme activity) achieved by either acarbose or (a) plant extracts and (b) individual catechins. Significant differences are denoted by unshared letters between columns as determined by ANOVA, as described under Materials and Methods.

Table 3. α -Glucosidase Inhibition by Tea and Grape Seed Extracts and Individual Catechins^a

extract		IC ₅₀ (μ g/mL)	IC ₉₀ (μ g/mL)	catechin		IC ₅₀ (μ g/mL)	IC ₉₀ (μ g/mL)
acarbose (control)	(n = 7)	91.0 \pm 10.8a	>645 ^b	C	(n = 2)	~31	>290 ^b
grape seed extract	(n = 3)	1.2 \pm 0.2b	2.1 \pm 0.2f	EC	(n = 2)	>290 ^b	ND
green tea extract	(n = 3)	0.5 \pm 0.1c	0.8 \pm 0.2g	EGC	(n = 2)	ND	ND
Teavigo	(n = 3)	0.3 \pm 0.1d	0.4 \pm 0.1g	ECG	(n = 3)	3.5 \pm 1.1be	13.9 \pm 4.1h
white tea extract	(n = 3)	2.5 \pm 0.4e	5.7 \pm 1.8fhi	EGCG	(n = 3)	0.3 \pm 0.1d	0.4 \pm 0.1g
				GCG	(n = 3)	1.4 \pm 0.1be	2.9 \pm 0.2i

^aValues presented are the mean \pm standard error, or approximate values if incomplete inhibition was observed. Different letters denote significant differences in IC₅₀ or IC₉₀ values as determined by unpaired *t* test (*p* < 0.05). ND, not determined. ^bExceeds maximum concentration tested.

DISCUSSION

Our data presented here suggest that extracts of grape seeds and tea as well as 3-gallated catechins show promise as potent glucosidase inhibitors that may limit the digestion of dietary starches. Grape seed and tea extracts are easily available sources of flavonoids, many of which have shown efficacy in controlling the symptoms of diabetes. Whereas all of these plant extracts are rich in flavan-3-ols (flavonoid molecules are characterized by their saturated C-ring and 3-OH group) green and white teas are particularly abundant in catechins, that is, flavan-3-ol monomers, whereas grape seed extract also contains dimeric, trimeric, and oligomeric flavan-3-ols, collectively called procyanidins. It is likely that these differences in extract composition explain the differences in α -amylase and α -glucosidase inhibition observed in the present paper.

Previous studies have determined several key structural features needed for monomeric flavonoids to inhibit α -amylase and α -glucosidase activity.^{10,22,24,26} In agreement with these previous studies,^{24,26} our data show that extracts abundant in catechins (white tea, green tea, and Teavigo) along with individual catechins (C, EC, EGC, ECG, GCG, and EGCG) are not particularly strong inhibitors of salivary α -amylase. This is likely due to the lack of an unsaturated C-ring with a 4-keto group in flavan-3-ols, and the lack of specific A- and B-ring hydroxyl groups in the correct stereospecific orientation to effectively interact with the catalytic site of the enzyme.²⁶

For α -glucosidase inhibition, the presence of a gallate group esterified to the 3-position of the C-ring has been suggested to be critical for the interaction of flavan-3-ols with the enzyme.^{10,22} Our data support this hypothesis, showing that α -glucosidase activity is strongly inhibited by catechin 3-gallates, whereas nongallated catechins are poor enzyme inhibitors. As green and white tea extracts are abundant in catechin 3-gallates,²⁸ primarily EGCG (Table 1), this would explain their relative potency against α -glucosidase activity. Interestingly, grape seed extract does not contain significant amounts of EGCG and other catechin 3-gallates; hence, its inhibitory effect on α -glucosidase must be due to some other constituent(s), possibly procyanidins or procyanidin gallates.^{19,20} Overall, the strongest inhibitors of α -glucosidase identified in our study were EGCG and Teavigo, which, on the basis of their IC_{50} values, were >300 times more potent than acarbose.

Our results further show that grape seed extract is as potent an α -amylase inhibitor as acarbose. Little is known about the mechanism by which grape seed extract inhibits α -amylase, although the interaction of various grape seed extracts with several digestive enzymes has been reported.^{21,22,25,29} Grape seed extracts can vary in composition on the basis of grape variety, growing season, and other factors. In general, they are similar to the composition listed in Table 1: 5–10% catechin and epicatechin, with an equivalent amount of smaller procyanidins. Because catechin and epicatechin were very weak, incomplete, inhibitors of α -amylase, it is likely that the procyanidins in grape seed extract are mainly responsible for the observed inhibitory effect on α -amylase activity. Interestingly, α -amylase normally binds polysaccharides longer than α -glucosidase, and acarbose is a pseudotetrasaccharide containing a nonhydrolyzable nitrogen-linked bond that suppresses α -amylase activity by competitive, reversible inhibition.³⁰ Similarly, procyanidins have a nonhydrolyzable oligomeric structure that may occupy the substrate binding pocket of α -amylase, thereby competitively inhibiting the enzyme. Furthermore, gallated procyanidin dimers found in

grape seeds have particular “closed” conformations that reportedly enhance interactions with α -amylase.²⁵ However, as grape seed extract is a complex mixture of procyanidins, further work is needed to detail these potential interactions of grape seed extract with α -amylase and provide a rationale for the interaction of grape seed extract with α -glucosidase.

To determine the true efficacy of grape seed and tea extracts as glucosidase inhibitors, studies in human subjects are necessary. As such, it is important to consider the interactions of these extracts with the gastrointestinal tract and how this may alter their inhibitory potential. Previous work has shown that both catechins and procyanidins are stable in the acidic environment of the stomach.^{31,32} However, there is some evidence that pancreatic digestion, along with a shift to a slightly alkaline pH in the duodenum, may cause degradation of the polymeric procyanidins to their respective monomeric components.^{32,33} In contrast, catechins generally remain stable during intestinal transit.³³ Despite this degradation of complex procyanidins, studies using simulated digestion models have shown that millimolar concentrations of catechins and procyanidins can be expected in the digestive tract following consumption of 300 mg of grape seed extracts.³² These concentrations (approximately 0.1–1.0 mg/mL depending on the compound in question) would approach the IC_{50} values of only the most potent inhibitors determined in this study, requiring further dose–response studies to be performed. In addition, nonspecific interactions of flavonoids with proteins in the gastric mucosa, intestine, or protein-rich foods may limit the interactions of catechins and procyanidins with glucosidases and require special preparations or the ingestion of large quantities of plant extracts to be effective.

In conclusion, our data suggest the use of plant extracts, especially grape seed and green tea extracts, as viable alternatives to pharmaceutical inhibitors of the glycoside hydrolase enzymes, α -amylase and α -glucosidase. Because these plant extracts are well tolerated, relatively inexpensive, and readily available, they have the potential to be used in many applications for glycemic control. Whereas EGCG appears to be mainly responsible for the inhibitory effects on α -glucosidase activity of the plant extracts investigated here, the contribution of other catechins and catechin 3-gallates should not be discounted. Although further work is required to determine if specific procyanidins are responsible for the inhibitory effects of grape seed extract on α -amylase activity, it is certainly possible that multiple components of the extract are needed to reach its full inhibitory potential. Clinical trials are currently planned to demonstrate the efficacy of these extracts and EGCG in human volunteers to lower postprandial hyperglycemia.

AUTHOR INFORMATION

Corresponding Author

*Phone: +1-(541) 737-5078. Fax: +1-(541) 737-5077. E-mail: balz.frei@oregonstate.edu.

Funding

This study was funded in part by USANA Health Sciences, Inc. (Salt Lake City, UT).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Deborah Hobbs and Dr. C.L. Miranda for their help and discussions.

■ ABBREVIATIONS USED

C, catechin; IC₅₀, concentration required for 50% inhibition of enzyme activity; IC₉₀, concentration required for 90% inhibition of enzyme activity; DMSO, dimethyl sulfoxide; EC, epicatechin; EGC, epigallocatechin; EGCG, epigallocatechin gallate; GCG, galocatechin gallate; ECG, epicatechin gallate; pNPG, *p*-nitrophenyl α -D-glucopyranoside.

■ REFERENCES

- (1) Skyler, J. S.; Bergenstal, R.; Bonow, R. O.; Buse, J.; Deedwania, P.; Gale, E. A.; Howard, B. V.; Kirkman, M. S.; Kosiborod, M.; Reaven, P.; Sherwin, R. S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Circulation* **2009**, *119*, 351–357.
- (2) Blonde, L. Benefits and risks for intensive glycemic control in patients with diabetes mellitus. *Am. J. Med. Sci.* **2012**, *343*, 17–20.
- (3) Bolen, S.; Feldman, L.; Vassy, J.; Wilson, L.; Yeh, H. C.; Marinopoulos, S.; Wiley, C.; Selvin, E.; Wilson, R.; Bass, E. B.; Brancati, F. L. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann. Intern. Med.* **2007**, *147*, 386–399.
- (4) Lebovitz, H. E. α -Glucosidase inhibitors. *Endocrinol. Metab. Clin. North Am.* **1997**, *26*, 539–551.
- (5) Fujisawa, T.; Ikegami, H.; Inoue, K.; Kawabata, Y.; Ogihara, T. Effect of two α -glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. *Metabolism* **2005**, *54*, 387–390.
- (6) Neuser, D.; Benson, A.; Bruckner, A.; Goldberg, R. B.; Hoogwerf, B. J.; Petzinna, D. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. *Clin. Drug Invest.* **2005**, *25*, 579–587.
- (7) Said, O.; Fulder, S.; Khalil, K.; Azaizeh, H.; Kassis, E.; Saad, B. Maintaining a physiological blood glucose level with 'glucoselevel', a combination of four anti-diabetes plants used in the traditional arab herbal medicine. *Evidence-Based Complement. Altern. Med.* **2008**, *5*, 421–8.
- (8) Bhat, M.; Zinjarde, S. S.; Bhargava, S. Y.; Kumar, A. R.; Joshi, B. N. Antidiabetic Indian plants: a good source of potent amylase inhibitors. *Evidence-Based Complement. Altern. Med.* **2011**, *2011*, 810207.
- (9) Benalla, W.; Bellahcen, S.; Bnouham, M. Antidiabetic medicinal plants as a source of α -glucosidase inhibitors. *Curr. Diabetes Rev.* **2010**, *6*, 247–254.
- (10) Kamiyama, O.; Sanae, F.; Ikeda, K.; Higashi, Y.; Minami, Y.; Asano, N.; Adachi, I.; Kato, A. In vitro inhibition of α -glucosidases and glycogen phosphorylase by catechin gallates in green tea. *Food Chem.* **2010**, *122*, 1061–1066.
- (11) Li, Y. Q.; Zhou, F. C.; Gao, F.; Bian, J. S.; Shan, F. Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of α -glucosidase. *J. Agric. Food Chem.* **2009**, *57*, 11463–11468.
- (12) McDougall, G. J.; Shpiro, F.; Dobson, P.; Smith, P.; Blake, A.; Stewart, D. Different polyphenolic components of soft fruits inhibit α -amylase and α -glucosidase. *J. Agric. Food Chem.* **2005**, *53*, 2760–2766.
- (13) Wolfram, S. Effects of green tea and EGCG on cardiovascular and metabolic health. *J. Am. Coll. Nutr.* **2007**, *26*, 373S–388S.
- (14) Nahas, R.; Moher, M. Complementary and alternative medicine for the treatment of type 2 diabetes. *Can. Fam. Physician* **2009**, *55*, 591–596.
- (15) Kar, P.; Laight, D.; Rooprai, H. K.; Shaw, K. M.; Cummings, M. Effects of grape seed extract in type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. *Diabetes Med.* **2009**, *26*, 526–531.
- (16) Montagut, G.; Blade, C.; Blay, M.; Fernandez-Larrea, J.; Pujadas, G.; Salvado, M. J.; Arola, L.; Pinent, M.; Ardevol, A. Effects of a grape seed procyanidin extract (GSPE) on insulin resistance. *J. Nutr. Biochem.* **2010**, *21*, 961–967.
- (17) Yan, J.; Zhao, Y.; Suo, S.; Liu, Y.; Zhao, B. Green tea catechins ameliorate adipose insulin resistance by improving oxidative stress. *Free Radical Biol. Med.* **2012**, *52*, 1648–1657.
- (18) Park, J. H.; Jin, J. Y.; Baek, W. K.; Park, S. H.; Sung, H. Y.; Kim, Y. K.; Lee, J.; Song, D. K. Ambivalent role of galled catechins in glucose tolerance in humans: a novel insight into non-absorbable galled catechin-derived inhibitors of glucose absorption. *J. Physiol. Pharmacol.* **2009**, *60*, 101–109.
- (19) Mandic, A. I.; Đilas, S. M.; Četković, G. S.; Čanadanović-Brunet, J. M.; Tumbas, V. T. Polyphenolic composition and antioxidant activities of grape seed extract. *Int. J. Food Prop.* **2008**, *11*, 713–726.
- (20) Khanal, R. C.; Howard, L. R.; Prior, R. L. Procyanidin content of grape seed and pomace, and total anthocyanin content of grape pomace as affected by extrusion processing. *J. Food Sci.* **2009**, *74*, H174–H182.
- (21) Soares, S.; Mateus, N.; Freitas, V. Interaction of different polyphenols with bovine serum albumin (BSA) and human salivary α -amylase (HSA) by fluorescence quenching. *J. Agric. Food Chem.* **2007**, *55*, 6726–6735.
- (22) Gamberucci, A.; Konta, L.; Colucci, A.; Giunti, R.; Magyar, J. E.; Mandl, J.; Banhegyi, G.; Benedetti, A.; Csala, M. Green tea flavonols inhibit glucosidase II. *Biochem. Pharmacol.* **2006**, *72*, 640–646.
- (23) Koh, L. W.; Wong, L. L.; Loo, Y. Y.; Kasapis, S.; Huang, D. Evaluation of different teas against starch digestibility by mammalian glycosidases. *J. Agric. Food Chem.* **2010**, *58*, 148–154.
- (24) Tadera, K.; Minami, Y.; Takamatsu, K.; Matsuoka, T. Inhibition of α -glucosidase and α -amylase by flavonoids. *J. Nutr. Sci. Vitaminol. (Tokyo)* **2006**, *52*, 149–153.
- (25) de Freitas, V.; Mateus, N. Structural features of procyanidin interactions with salivary proteins. *J. Agric. Food Chem.* **2001**, *49*, 940–945.
- (26) Lo Piparo, E.; Scheib, H.; Frei, N.; Williamson, G.; Grigorov, M.; Chou, C. J. Flavonoids for controlling starch digestion: structural requirements for inhibiting human α -amylase. *J. Med. Chem.* **2008**, *51*, 3555–3561.
- (27) Deuschlander, M. S.; van de Venter, M.; Roux, S.; Louw, J.; Lall, N. Hypoglycaemic activity of four plant extracts traditionally used in South Africa for diabetes. *J. Ethnopharmacol.* **2009**, *124*, 619–624.
- (28) Zhao, Y.; Chen, P.; Lin, L.; Harnly, J. M.; Yu, L.; Li, Z. Tentative identification, quantitation, and principal component analysis of green pu-erh, green, and white teas using UPLC/DAD/MS. *Food Chem.* **2011**, *126*, 1269–1277.
- (29) Mateus, N.; Pinto, R.; Ruão, P.; de Freitas, V. Influence of the addition of grape seed procyanidins to Port wines in the resulting reactivity with human salivary proteins. *Food Chem.* **2004**, *84*, 195–200.
- (30) Truscheit, E.; Frommer, W.; Junge, B.; Müller, L.; Schmidt, D. D.; Wingender, W. Chemistry and biochemistry of microbial α -glucosidase inhibitors. *Angew. Chem., Int. Ed.* **1981**, *20*, 744–761.
- (31) Rios, L.; Benett, R.; Lazarus, S.; Rémésy, C.; Scalbert, A.; Williamson, G. Cocoa procyanidins are stable during gastric transit in humans. *Am. J. Clin. Nutr.* **2002**, *76*, 1106–1110.
- (32) Serra, A.; Maciá, A.; Romero, M.; Valls, J.; Bladé, C.; Arola, L.; Motilva, M. Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. *Brit. J. Nutr.* **2009**, *103*, 944–952.
- (33) Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am. J. Clin. Nutr.* **2005**, *81*, 230S–242S.